Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Entities affiliated with RA Capital Management reported open-market purchases of a total of 21,654 shares of Artiva Biotherapeutics common stock on 2026-07-10 and 2026-07-13 at weighted-average prices of $8.9700 and $8.9400 per share. After these trades they report 16,817,573.0000 shares of common stock held indirectly across several managed funds and a separately managed account, while disclaiming beneficial ownership beyond their pecuniary interests.
Artiva Biotherapeutics, Inc. disclosed that investment vehicles managed by RA Capital Management, L.P. made net open-market purchases of 32,876 shares of its common stock. On June 25, 2026, a fund associated with RA Capital bought 31,000 shares at a weighted average price of $8.88 per share, and on June 26, 2026, a related account bought 1,876 shares at a weighted average price of $8.98 per share. Footnotes state these trades occurred in multiple transactions within price ranges of $8.62–$8.98 and $8.97–$9.00. After these transactions, RA Capital–managed entities collectively report indirect holdings in several blocks, including 16,795,919 shares in one fund, reflecting a large existing position with a relatively small incremental purchase.
Artiva Biotherapeutics, Inc. reported open-market purchases of its common stock by investment funds and accounts managed by RA Capital Management, L.P. The transactions covered a total of 531,326 shares at prices around $8.57 to $8.99 per share, with weighted-average prices within disclosed ranges of $8.31 to $9.00. Following these buys, the largest reported indirect position among the reporting entities was 16,763,043 shares of common stock. The Adviser, its general partner and related individuals and funds disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
RA Capital Management and affiliates report beneficial ownership of 17,811,623 shares of Artiva Biotherapeutics common stock, representing 36.6% of the class. The stake is held across RA Capital Healthcare Fund, related Nexus funds, a managed account, pre-funded warrants, and stock options.
The Fund recently bought additional shares in open market transactions on June 9, 10, 11, 12, and 15, 2026 at prices ranging from $6.77 to $9.00 per share, funded with its working capital. A 9.99% Beneficial Ownership Blocker currently prevents exercising the pre-funded warrants.
Artiva Biotherapeutics, Inc. insider filing shows affiliated RA Capital funds buying additional common stock in open-market transactions. Entities managed by RA Capital purchased a total of 1,027,722 Artiva shares between June 9 and June 11, 2026 at prices around $6.91–$7.91 per share.
After these indirect purchases through RA Capital-managed vehicles, the reporting group is shown holding 16,231,717 shares of Artiva common stock. Footnotes state the adviser and related parties disclaim beneficial ownership except to the extent of their pecuniary interest.
Artiva Biotherapeutics received an updated ownership disclosure from GC Corp, GC Cell Corporation and Yong‑Jun Huh following their participation in Artiva’s May 2026 underwritten offering. GC Corp bought 1,085,069 shares and GC Cell Corporation bought 347,222 shares of common stock at $11.52 per share.
After these purchases, GC Corp is reported as beneficially owning 5,999,703 shares, or 12.3% of Artiva’s common stock, and GC Cell Corporation 1,607,734 shares, or 3.3%, based on 48,588,198 shares outstanding. Yong‑Jun Huh may be deemed a beneficial owner of the shares held by GC Corp and GC Cell for Section 13(d) purposes but expressly disclaims beneficial ownership for other purposes.
GC Corp. and subsidiary GC Cell Corporation, both 10% owners of Artiva Biotherapeutics, Inc., bought a combined 1,432,291 shares of Artiva common stock in open‑market transactions. The purchases were made on May 11, 2026 at $11.52 per share.
After these transactions, GC Cell Corporation held 1,607,734 Artiva shares indirectly and GC Corp. held 4,391,969 shares directly. Footnotes explain that GC Corp. is a Korean holding company ultimately controlled by its board, whose members may be deemed to share voting and investment power but each disclaims beneficial ownership except for any pecuniary interest.
Artiva Biotherapeutics, Inc. senior vice president of research and development Heather Raymon reported an open-market sale of 3,095 shares of common stock at a weighted average price of $9.0078 per share. According to the company’s sell-to-cover policy, these shares were sold automatically to satisfy tax withholding on vested restricted stock units. After this transaction, Raymon directly holds 148,228 Artiva shares.
Artiva Biotherapeutics, Inc. reported that Chief Tech Operations Officer Christopher Horan sold 7,002 shares of common stock on May 19, 2026 at a weighted average price of $9.0078 per share. The price range for these sales was between $8.7421 and $9.0104.
According to the company’s sell-to-cover policy, these automatic sales were made solely to cover tax withholding obligations arising from the vesting and release of restricted stock units, and were not discretionary trades. After the transaction, Horan directly owned 293,450 shares of Artiva common stock.
Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units. The shares were sold in the open market at a weighted average price of $9.0078 per share, within a range of $8.7439 to $9.0104. After this sell-to-cover transaction under the company’s tax policy, she continues to hold 337,920 shares directly.